Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism

This study was designed to establish the mechanism responsible for the increased apolipoprotein (apo) A-II levels caused by the cholesteryl ester transfer protein inhibitor torcetrapib. Nineteen subjects with low HDL cholesterol (<40 mg/dl), nine of whom were also treated with 20 mg of atorvastat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brousseau, Margaret E., Millar, John S., Diffenderfer, Margaret R., Nartsupha, Chorthip, Asztalos, Bela F., Wolfe, Megan L., Mancuso, James P., Digenio, Andres G., Rader, Daniel J., Schaefer, Ernst J.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Biochemistry and Molecular Biology 2009
Matèries:
Patient-Oriented and Epidemiological Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2694343/
https://ncbi.nlm.nih.gov/pubmed/19193611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.P800037-JLR200
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars